VP2 virus‐like particles elicit protective immunity against duckling short beak and dwarfism syndrome in ducks
2022
Xiao, Shifeng | Wang, Shao | Jiang, Dandan | Cheng, Xiaoxia | Zhu, Xiaoli | Lin, Fengqiang | Yu, Bo | Dong, Hui | Wang, Xiuzhen | Munīr, Muhammad | Rohaim, Mohammed A. | Chen, Shilong | Chen, Shaoying
Duckling short beak and dwarfism syndrome virus (SBDSV), an emerging goose parvovirus, has caused short beak and dwarfism syndrome (SBDS) in Chinese duck flocks since 2015. Presently, there is no commercial vaccine against SBDS. In the present study, a virus‐like particle (VLP)‐based candidate vaccine was developed against this disease. A baculovirus expression system was used to express the SBDSV VP2 protein in Sf9 cells. Immunofluorescence assay, sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS‐PAGE) and Western blotting were used to confirm protein expression. Furthermore, transmission electron microscopy was used to observe the formation of VLPs. VLPs were formulated into an oil‐adjuvanted maternal vaccine to evaluate humoral responses in breeding ducks via latex particle agglutination inhibition assay (LPAI) and microneutralization assay. The offspring were challenged with SBDSV to test the protective efficacy. A single dose of SBDSV was able to induce the high level of LPAI antibodies in ducks, with LPAI and neutralization peak titres of 4.9 ± 1.20 log2 and 7.1 ± 1.20 log2, respectively, at 4 weeks post‐vaccination (wpv). The average LPAI titre of yolk antibodies in duck eggs receiving 2 doses (first and boost doses) of the vaccine was 5.3 ± 1.09 log2 at 4 weeks post‐boost. The protective efficacy of the maternal vaccine was 87.5%–100%. These results indicate that SBDSV VLPs can be a promising vaccine candidate for controlling SBDS.
显示更多 [+] 显示较少 [-]